Indication
Amversio is indicated as adjunctive treatment of homocystinuria, involving deficiencies or defects in: cystathionine beta-synthase (CBS), 5,10 methylene tetrahydrofolate reductase (MTHFR), cobalamin cofactor metabolism (cbl).
Loading your page…
Homocystinuria
Marketing Authorisation Holder: SERB SA
EMA Authorisation: 05/05/2022
INN: betaine anhydrous
AI Drug & Interaction Analysis
Free account required
Ask Osler about Amversio: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.